Healthy Volunteers (Intended Indication: Metastatic Patients With Triple Negative or HR+ Breast Cancer, or Hormone Sensitive Prostate Cancer) Clinical Trial
Official title:
An Open-label, Fixed Sequence Study in Healthy Subjects to Assess the Pharmacokinetics of Capivasertib When Administered Alone and In Combination With Itraconazole
| Verified date | April 2021 |
| Source | AstraZeneca |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
This study will be an open-label, fixed sequence study in healthy subjects (vasectomized males and females of non-childbearing potential), performed at a single study centre.
| Status | Completed |
| Enrollment | 11 |
| Est. completion date | March 25, 2021 |
| Est. primary completion date | March 25, 2021 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | All |
| Age group | 18 Years to 58 Years |
| Eligibility | Inclusion Criteria: - Provision of signed and dated, written informed consent prior to any study specific procedures. - Healthy male and female subjects aged 18 to 58 years with suitable veins for cannulation or repeated venipuncture. - Females must have a negative pregnancy test at screening and on admission to the study centre, must not be lactating and must be of non-childbearing potential, confirmed at screening. - Male subjects must be vasectomized (at least 6 months prior to the Screening Visit), with documented post-procedural medical assessment of surgical success. - Have a body mass index between 18 and 28 kg/m^2 inclusive and weigh at least 50 kg and no more than 100 kg inclusive. - Non-smoker, defined as a subject who has not smoked previously or who has discontinued smoking or the use of other nicotine/nicotine-containing products. Exclusion Criteria: - History of any clinically significant disease or disorder which, in the opinion of the Investigator, may either put the volunteer at risk because of participation in the study, or influence the results or the volunteer's ability to participate in the study. - History or presence of gastrointestinal, hepatic or renal disease, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs; abnormalities in haematology, clinical chemistry, or urinalysis results, at screening or on admission to the study centre, as judged by the Investigator. - Any clinically significant abnormalities in glucose metabolism, blood lipid profiles , liver enzymes , vital signs , and 12-lead electrocardiogram. - Any positive result on screening for serum hepatitis B surface antigen (HBsAg) or antibody to hepatitis B core antigen (anti-HBc), hepatitis C antibody (anti-HCV), and human immunodeficiency virus (HIV) antibody. - History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity, as judged by the Investigator. - Positive screen for drugs of abuse, alcohol and/or cotinine at screening or on admission to the study centre. - Subjects who have previously received capivasertib. - Subject has a positive test result for Severe acute respiratory syndrome (SARS)-Coronavirus (CoV)-2 Reverse Transcriptase (RT)-Polymerase Chain Reaction (PCR) before randomization. - Subject has clinical signs and symptoms consistent with corona virus disease 2019 (COVID-19) (e.g., fever, dry cough, dyspnoea, sore throat, anosmia/hyposmia, loss or reduced taste, and fatigue) or confirmed infection by appropriate laboratory test within the last 4 weeks prior to screening or on admission. - Subjects who are regularly exposed to the risk of COVID-19 infection as part of their daily life (e.g., health care professionals working in COVID-19 wards or at emergency departments). |
| Country | Name | City | State |
|---|---|---|---|
| Germany | Research Site | Berlin |
| Lead Sponsor | Collaborator |
|---|---|
| AstraZeneca | Parexel |
Germany,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Area under plasma concentration-time curve from zero to infinity (AUCinf) of capivasertib | Assessment of AUCinf of capivasertib. | Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 36, and 48 hours after capivasertib dose on Day 1 and Day 6 | |
| Primary | Maximum observed plasma (peak) drug concentration (Cmax) of capivasertib | Assessment of Cmax of capivasertib. | Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 36, and 48 hours after capivasertib dose on Day 1 and Day 6 | |
| Secondary | Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUClast) of capivasertib and its major metabolite (AZ14102143) | Assessment of AUClast of capivasertib and its major metabolite (AZ14102143). | Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 36, and 48 hours after capivasertib dose on Day 1 and Day 6 | |
| Secondary | Time delay between drug administration and the first observed concentration in plasma (tlag) of capivasertib | Assessment of tlag of capivasertib. | Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 36, and 48 hours after capivasertib dose on Day 1 and Day 6 | |
| Secondary | Time to reach peak or maximum observed concentration or response following drug administration (tmax) of capivasertib and its major metabolite (AZ14102143) | Assessment of tmax of capivasertib and its major metabolite (AZ14102143). | Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 36, and 48 hours after capivasertib dose on Day 1 and Day 6 | |
| Secondary | Half-life associated with terminal slope (?z) of a semi-logarithmic concentration time curve (t½?z) of capivasertib and its major metabolite (AZ14102143) | Assessment of t½?z of capivasertib and its major metabolite (AZ14102143). | Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 36, and 48 hours after capivasertib dose on Day 1 and Day 6 | |
| Secondary | Terminal elimination rate constant (?z) of capivasertib and its major metabolite (AZ14102143) | Assessment of ?z of capivasertib and its major metabolite (AZ14102143). | Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 36, and 48 hours after capivasertib dose on Day 1 and Day 6 | |
| Secondary | Apparent total body clearance of drug from plasma after extravascular administration (CL/F) of capivasertib | Assessment of CL/F of capivasertib. | Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 36, and 48 hours after capivasertib dose on Day 1 and Day 6 | |
| Secondary | Volume of distribution (apparent) at steady state following extravascular administration (Vz/F) (based on terminal phase) of capivasertib | Assessment of Vz/F of capivasertib. | Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 36, and 48 hours after capivasertib dose on Day 1 and Day 6 | |
| Secondary | AUCinf of major metabolite (AZ14102143) of capivasertib | Assessment of AUCinf of major metabolite (AZ14102143) of capivasertib. | Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 36, and 48 hours after capivasertib dose on Day 1 and Day 6 | |
| Secondary | Cmax of major metabolite (AZ14102143) of capivasertib | Assessment of Cmax of major metabolite (AZ14102143) of capivasertib. | Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 36, and 48 hours after capivasertib dose on Day 1 and Day 6 | |
| Secondary | Number of subjects with serious and non-serious adverse events | Assessment of safety and tolerability of capivasertib alone and in combination with itraconazole. | From Screening until Follow-upVisit / Early Termination (7-14 days after last PK sample) |